- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06793397
주요 우울 장애에서 CYB003을 평가하기위한 3 상 시험 (EMBRACE)
효능 및 안전성, III 상, 다중 센터, 이중 맹검, 무작위 대조 연구, 주요 우울 장애가있는 적격 참가자에서 2 개의 활성 용량 및 위약을 비교하는 2 개의 활성 용량을 비교합니다.
The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD.
For more information about the EMBRACE study, including participating study locations, and to register your interest in learning more about participation, please visit the study website: https://embrace-mdd-trial.com/
연구 개요
상태
개입 / 치료
연구 유형
등록 (추정된)
단계
- 3단계
연락처 및 위치
연구 연락처
- 이름: Clinical Development
- 전화번호: 877-361-4003
- 이메일: clinicaltrialsinfo@cybin.com
연구 장소
-
-
-
Athens, 그리스, 12462
- 모병
- Attikon University Hospital
-
수석 연구원:
- Nikolaos Smyrnis
-
연락하다:
- Thomas Karantinos
- 전화번호: +30697466610
- 이메일: tkarantinos@gmail.com
-
Athens, 그리스, 11528
- 모병
- Eginitio Hospital
-
수석 연구원:
- Nikos Stefanis
-
연락하다:
- Adam Adamopoulos
- 전화번호: +30 6976032181
- 이메일: adam_adamopoulos@yahoo.com
-
Thessaloniki, 그리스, 56404
- 모병
- Papageorgiou General Hospital
-
수석 연구원:
- Georgios Papazisis
-
연락하다:
- Ogla Vampertzi
- 전화번호: +306973852659
- 이메일: olgatrieste@hotmail.com
-
-
-
-
-
Berlin, 독일, 10117
- 아직 모집하지 않음
- Charité Universitaetsmedizin Berlin
-
수석 연구원:
- Michael Koslowski
-
연락하다:
- 전화번호: +49 30 450 617734
- 이메일: psychedelika-studien@charite.de
-
Frankfurt am Main, 독일, 60528
- 아직 모집하지 않음
- University Hospital Frankfurt
-
수석 연구원:
- Andreas Reif
-
연락하다:
- Tanja Scharf
- 전화번호: +49 69 6301 86078
- 이메일: tanja.scharf@unimedizin-ffm.de
-
Mannheim, 독일, 68159
- 아직 모집하지 않음
- Central Institute of Mental Health
-
연락하다:
- Karin Bopp
- 전화번호: 3016 +49 621 1703 3163
- 이메일: Karin.bopp@zi-mannheim.de
-
수석 연구원:
- Gerhard Grüender
-
-
Saarland
-
Homburg, Saarland, 독일, 66421
- 아직 모집하지 않음
- Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes
-
수석 연구원:
- Matthias Riemenschneider
-
연락하다:
- Christine Geiger
- 전화번호: +49 6841 1624227
- 이메일: christine.geiger@uks.eu
-
연락하다:
- Aline Freer
- 전화번호: +49 6841 1614219
- 이메일: aline.freer@uks.eu
-
-
-
-
Alabama
-
Birmingham, Alabama, 미국, 35209
- 모병
- UAB Psychiatry and Behavioral Neurology
-
연락하다:
- Seher Premani
- 전화번호: 205-996-1198
- 이메일: spremani@uab.edu
-
수석 연구원:
- Peter Hendricks
-
연락하다:
- Maggie Gossage
- 이메일: mgossage@uabmc.edu
-
-
Arizona
-
Gilbert, Arizona, 미국, 85234
- 모병
- Lighthouse Psychiatry
-
연락하다:
- Chung Trinh
- 전화번호: 435-268-5800
- 이메일: ctrinh@neosciclinicalresearch.com
-
수석 연구원:
- Frank Genova
-
-
Arkansas
-
Little Rock, Arkansas, 미국, 72204
- 빼는
- Pillar Clinical Research - Little Rock
-
-
California
-
Glendale, California, 미국, 91206
- 모병
- Behavioral Research Specialists, LLC
-
수석 연구원:
- Jesse Carr
-
연락하다:
- Laisha Uribe
- 전화번호: 888-255-5798
- 이메일: laisha@brstrials.com
-
Imperial, California, 미국, 92251
- 빼는
- Sun Valley Research Center
-
Los Angeles, California, 미국, 90025
- 모병
- CalNeuro Research Group
-
수석 연구원:
- Alexander Bystritsky
-
연락하다:
- 전화번호: 310-208-7144
- 이메일: info@calneuroresearch.com
-
Los Angeles, California, 미국, 90025
- 모병
- Lipov Medical Group
-
연락하다:
- Brittany Juhlmann
- 전화번호: 262-352-8835
- 이메일: brittany.juhlmann@stellacenter.com
-
수석 연구원:
- Jacob Moussai
-
Orange, California, 미국, 92868
- 모병
- NRC Research Institute
-
연락하다:
- Christian Ortiz
- 전화번호: 714-289-1100
- 이메일: cortiz@nrcresearch.com
-
수석 연구원:
- Daniel Chueh
-
Orange, California, 미국, 92866
- 모병
- ATP Clinical Research
-
수석 연구원:
- Gustavo Alva
-
연락하다:
- Sarah Perkins
- 전화번호: 949-354-5353
- 이메일: sarahp@pnsoc.com
-
San Juan Capistrano, California, 미국, 92675
- 모병
- Inland Psychiatric Medical Group Inc (IPMG Research)
-
수석 연구원:
- Neelima Kunam
-
연락하다:
- 전화번호: 909-955-5865
- 이메일: research@inlandpsych.com
-
Santa Monica, California, 미국, 90404
- 모병
- Psychedelic Science Institute
-
수석 연구원:
- Keith Heinzerling
-
연락하다:
- 전화번호: 213-973-7512
- 이메일: trialadmin@psychedelicsci.com
-
Stanford, California, 미국, 94305
- 빼는
- Stanford University
-
-
Connecticut
-
New Haven, Connecticut, 미국, 06511
- 모병
- Yale School of Medicine - Yale Program for Psychedelic Science
-
수석 연구원:
- Ben Kelmendi
-
연락하다:
- Daidre Chamberlain
- 전화번호: 203-693-1591
- 이메일: enact@yale.edu
-
연락하다:
- Terrence Ching
- 전화번호: 502-612-1127
- 이메일: terence.ching@yale.edu
-
-
Florida
-
Jacksonville, Florida, 미국, 32256
- 모병
- CNS Healthcare
-
연락하다:
- 전화번호: 904-281-5757
-
수석 연구원:
- John Mark Joyce
-
Maitland, Florida, 미국, 32751
- 모병
- Accel Research Sites - Maitland
-
연락하다:
- 전화번호: 407-644-1165
-
수석 연구원:
- Andrea Marrafino
-
Naples, Florida, 미국, 34105
- 모병
- Aqualane Clinical Research
-
수석 연구원:
- Matthew Baker
-
연락하다:
- Rachel Novella
- 전화번호: 239-529-6780
- 이메일: Rachel@Aqualaneresearch.com
-
Tampa, Florida, 미국, 33634
- 모병
- K2 Medical Research Tampa
-
수석 연구원:
- Kelley Wilson
-
연락하다:
- Jessica Myers
- 전화번호: 352-500-5252
- 이메일: Jessica.Myers@k2med.com
-
-
Georgia
-
Atlanta, Georgia, 미국, 30329
- 빼는
- Emory University Dept of Psychiatry and Behavioral Studies
-
Marietta, Georgia, 미국, 30060
- 모병
- Psych Atlanta
-
수석 연구원:
- Michael Banov
-
연락하다:
- 전화번호: 770-422-2846
- 이메일: research@hightophealth.com
-
-
Illinois
-
Chicago, Illinois, 미국, 60612
- 모병
- Rush University
-
수석 연구원:
- Joshua Eloge
-
연락하다:
- Stephanie Gutierrez
- 전화번호: 312-942-8995
- 이메일: stephanie_z_gutierrez@rush.edu
-
-
Louisiana
-
Marrero, Louisiana, 미국, 70006
- 빼는
- Tandem Clinical Research
-
New Orleans, Louisiana, 미국, 70115
- 모병
- Atlas Psychiatry
-
연락하다:
- Milton Boresoff
- 전화번호: 504-899-1682
- 이메일: m.boresoff@atlaspsychiatry.com
-
수석 연구원:
- Nicholas Pejic
-
-
Maryland
-
Baltimore, Maryland, 미국, 21224
- 빼는
- Johns Hopkins Medicine
-
Rockville, Maryland, 미국, 20850
- 아직 모집하지 않음
- Sunstone Medical, PC
-
연락하다:
- Manish Agrawal, MD
- 전화번호: 301-750-3401
- 이메일: Manish.agrawal@sunstonetherapies.com
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02116
- 모병
- Adams Clinical Boston
-
수석 연구원:
- Darin Dougherty
-
연락하다:
- Participant Navigators
- 전화번호: 617-404-4714
- 이메일: info@adamsclinical.com
-
Watertown, Massachusetts, 미국, 02472
- 모병
- Adams Clinical Watertown
-
수석 연구원:
- Stephanie Ellickson
-
연락하다:
- Participant Navigators
- 전화번호: 617-404-4714
- 이메일: info@adamsclinical.com
-
-
Minnesota
-
Eden Prairie, Minnesota, 미국, 55347
- 모병
- Institute for Integrative Therapies
-
수석 연구원:
- Manoj Doss
-
연락하다:
- Sena Ostwalt
- 전화번호: 6512808774
- 이메일: sena.ostwalt@iit-mn.com
-
Golden Valley, Minnesota, 미국, 55427
- 아직 모집하지 않음
- The Remedy Mental Health
-
연락하다:
- Emmanuel Arhin
- 전화번호: (651) 382-9518
- 이메일: emmanuel.arhin@theremedymn.com
-
수석 연구원:
- Wayne Bentham
-
-
Nevada
-
Las Vegas, Nevada, 미국, 89119
- 모병
- Redbird Research, LLC
-
수석 연구원:
- Jelena Kunovac
-
연락하다:
- 전화번호: 702-577-2000
- 이메일: info@redbird-research.com
-
-
New Jersey
-
Toms River, New Jersey, 미국, 08755
- 모병
- Bio Behavioral Health
-
연락하다:
- Jessica Sutton
- 전화번호: 732-244-2299
- 이메일: jessica@bbhnj.com
-
수석 연구원:
- Ashok Patel
-
-
New York
-
New York, New York, 미국, 10032
- 아직 모집하지 않음
- New York State Psychiatric Institute
-
수석 연구원:
- Natalie Gukasyan
-
연락하다:
- Alexandra Mackay
- 전화번호: 212-342-1424
- 이메일: alexandra.mackay@nyspi.columbia.edu
-
New York, New York, 미국, 10029
- 모병
- Adams Clinical Harlem
-
연락하다:
- Participant Navigators
- 전화번호: 917-454-3746
- 이메일: info@adamsclinical.com
-
수석 연구원:
- Wesley Gregory
-
The Bronx, New York, 미국, 10461
- 모병
- Adams Clinical Bronx
-
수석 연구원:
- Shama Farooq
-
연락하다:
- Participant Navigators
- 전화번호: 917-454-3746
- 이메일: info@adamsclinical.com
-
-
Oklahoma
-
Oklahoma City, Oklahoma, 미국, 73112
- 빼는
- SP Research PLLC
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19104
- 모병
- Adams Clinical Philadelphia
-
수석 연구원:
- Cassie Blanchard
-
연락하다:
- Participant Navigators
- 전화번호: 267-376-0266
- 이메일: info@adamsclinical.com
-
Philadelphia, Pennsylvania, 미국, 19462
- 모병
- Flourish Research Philadelphia
-
수석 연구원:
- Rachna Saralkar
-
연락하다:
- 전화번호: 215-614-5606
-
-
Texas
-
Austin, Texas, 미국, 78737
- 빼는
- Austin Clinical Trial Partners
-
DeSoto, Texas, 미국, 75115
- 모병
- Adams Clinical Dallas
-
수석 연구원:
- Rajinder Shiwach
-
연락하다:
- Participant Navigators
- 전화번호: 469-379-2494
- 이메일: info@adamsclinical.com
-
Fort Worth, Texas, 미국, 76104
- 빼는
- North Texas Clinical Trials
-
Houston, Texas, 미국, 77046
- 모병
- Brain Health Consultants and TMS Center
-
수석 연구원:
- Lauren Marangell
-
연락하다:
- 전화번호: 713-489-5000
- 이메일: info@brainhealthconsultants.com
-
San Antonio, Texas, 미국, 78229
- 모병
- Flourish Research San Antonio
-
수석 연구원:
- Parke Hedges
-
연락하다:
- Xavier Martinez
- 전화번호: 237 210-949-0122
- 이메일: xmartinez@flourishresearch.com
-
연락하다:
- Andrea Gomez
- 전화번호: 122 210-949-0122
- 이메일: agomez@flourishresearch.com
-
-
Washington
-
Everett, Washington, 미국, 98201
- 아직 모집하지 않음
- Core Clinical Research
-
연락하다:
- Maria Golescu
- 전화번호: 425-443-9551
- 이메일: maria.golescu@ccrtrial.com
-
수석 연구원:
- James Knutson
-
Seattle, Washington, 미국, 98104
- 모병
- Seattle Neuropsychiatric Treatment Center
-
수석 연구원:
- Rebecca Allen
-
연락하다:
- 전화번호: 5 206-467-6300
- 이메일: research@seattlentc.com
-
-
-
-
-
Dublin, 아일랜드, D24 WK80
- 모병
- Sheaf House - Tallaght Adult Mental Health Service
-
수석 연구원:
- John Kelly
-
연락하다:
- Ann Connolly
- 전화번호: +353 8616 79619
- 이메일: aconnolly@crp.healthcare
-
Galway, 아일랜드, H91 VE03
- 모병
- La Nua Day Hospital Mental Health Centre
-
연락하다:
- Prathyusha Nedunuru
- 전화번호: +353 874283750
- 이메일: pnedunuru@crp.healthcare
-
수석 연구원:
- Shane McInerney
-
-
-
-
-
Cambridge, 영국, CB1 2EU
- 모병
- Cambridge University Hospital NHS
-
수석 연구원:
- Liliana Galindo
-
연락하다:
- Tracy Assari
- 전화번호: +44 1223 219751
- 이메일: t.assari@nhs.net
-
연락하다:
- Emma Tudor
- 전화번호: +44 1223 219751
- 이메일: Emma.tudor@cpft.nhs
-
Doncaster, 영국, DN4 8QN
- 모병
- Clerkenwell Health - Doncaster
-
수석 연구원:
- Paul Morrison
-
연락하다:
- Celia Creaghan
- 전화번호: +44 7849 640886
- 이메일: ccreaghan@clerkenwellhealth.com
-
Edinburgh, 영국, EH16 4TJ
- 아직 모집하지 않음
- NHS Research Scotland
-
수석 연구원:
- Donald MacIntyre
-
연락하다:
- Carrie Wardhaugh
- 전화번호: +44 1315375867
- 이메일: carrie.wardhaugh@ed.ac.uk
-
Glasgow, 영국, G51 4TF
- 아직 모집하지 않음
- Queen Elizabeth University Hospital
-
수석 연구원:
- Maytal Wolfe
-
연락하다:
- Rebecca Baird
- 이메일: ggc.mentalhealthresearch@nhs.scot
-
Liverpool, 영국, L7 8XP
- 아직 모집하지 않음
- Royal Liverpool Hospital
-
연락하다:
- Rachel Crick
- 전화번호: +44730 861 3597
- 이메일: Rachel.Crick@merseycare.nhs.uk
-
수석 연구원:
- Fabian Devlin
-
London, 영국, EC2Y 8EA
- 모병
- St Pancras Clinical Research
-
수석 연구원:
- Martin Johnson
-
연락하다:
- Participant Engagement Team
- 전화번호: +44 20 38651142
- 이메일: studyinformation@stpancrasclinical.com
-
London, 영국, W1U 6RP
- 모병
- Clerkenwell Health - Baker Street
-
수석 연구원:
- Alishah Suleman
-
연락하다:
- Takunda Gwenhure
- 전화번호: +44 2038974867
- 이메일: tgwenhure@clerkenwellhealth.com
-
연락하다:
- Victor Jardim
- 전화번호: +44 2038974867
- 이메일: vjardim@clerkenwellhealth.com
-
London, 영국, W1G9 RU
- 모병
- Re:Cognition Health
-
수석 연구원:
- Dimitrios Paschos
-
연락하다:
- 전화번호: +44-0800-802-1030
-
London, 영국, SE5 9RS
- 모병
- King's College London
-
연락하다:
- Catheine Bird
- 이메일: catherine.bird@kcl.ac.uk
-
연락하다:
- Paige Seath
- 이메일: paige.seath@kcl.ac.uk
-
수석 연구원:
- James Rucker
-
London, 영국, W1G 8DR
- 빼는
- Clerkenwell Health - Welbeck Street
-
Newcastle upon Tyne, 영국, NE4 5PL
- 모병
- Edwardson Building - Campus for Ageing and Vitality
-
연락하다:
- Victoria Wilson
- 전화번호: +44 191 246 8647
- 이메일: victoria.wilson3@cntw.nhs.uk
-
연락하다:
- Rebecca Woodhouse
- 이메일: Rebecca.Woodhouse@cntw.nhs.uk
-
수석 연구원:
- Mourad Wahba
-
Reading, 영국, RG7 8PA
- 모병
- Ascend Clinical Research
-
수석 연구원:
- Pamela Walters
-
연락하다:
- Alexandra Diaz
- 전화번호: +44 118 3045905
- 이메일: adiaz@ascendclinical-research.com
-
Sheffield, 영국, S4 7QQ
- 모병
- Sheffield Health and Social Care NHS Foundation Trust
-
수석 연구원:
- William Gann
-
연락하다:
- Mishell Cunningham
- 전화번호: +44 114 271 6731
- 이메일: mishell.cunningham@sheffieldpartnership.nhs.uk
-
-
-
-
-
Prague, 체코
- 아직 모집하지 않음
- Institute of neuropsychiatric Care (INEP)
-
수석 연구원:
- Alexander Nawka
-
연락하다:
- 전화번호: +420 222 201 020
- 이메일: info@inep.cz
-
Prague, 체코
- 아직 모집하지 않음
- Psyon s.r.o.
-
수석 연구원:
- Tomas Palenicek
-
연락하다:
- 전화번호: +420 774 401 161
- 이메일: info@psyon.cz
-
Předměstí, 체코
- 아직 모집하지 않음
- A-SHINE s.r.o.
-
수석 연구원:
- Lubos Janu
-
연락하다:
- Blanka Vopelková
- 전화번호: +490 777 732 244
- 이메일: blanka.vopelkova@seznam.cz
-
-
-
-
-
Bialystok, 폴란드, 15-272
- 빼는
- Uniwersytecki Szpital Kliniczny W Białymstoku
-
Bydgoszcz, 폴란드, 85-133
- 모병
- Promente - Centrum Neurologii i Psychogeriatrii w Bydgoszczy
-
연락하다:
- Franciszek Lauchut
- 전화번호: +48 790 219 501
- 이메일: f.lachut@pro-mente.pl
-
수석 연구원:
- Katarzyna Lachut
-
Gdansk, 폴란드, 80-546
- 모병
- Centrum Badan Klinicznych PI-House Sp. z o.o
-
연락하다:
- Monika Drzewiecka
- 전화번호: +48 508-348-938
- 이메일: m.drzewiecka@pihouse.pl
-
수석 연구원:
- Hanna Badzio-Jagiello
-
Gdansk, 폴란드, 80-214
- 아직 모집하지 않음
- UCK
-
수석 연구원:
- Wieslaw Jerzy Cubala
-
연락하다:
- Natalia Sudol
- 전화번호: +48 669 439 740
- 이메일: nat.sudol13@gmail.com
-
Warsaw, 폴란드, 02-957
- 아직 모집하지 않음
- Department of Pharmacology and Physiology of CNS
-
수석 연구원:
- Justyna Holka-Pokorska
-
Warsaw, 폴란드, 02-172
- 모병
- MTZ Clinical Research Powered by Pratia
-
수석 연구원:
- Monika Gawlowicz
-
-
-
-
New South Wales
-
Camperdown, New South Wales, 호주, 2050
- 모병
- Royal Prince Alfred Hospital
-
수석 연구원:
- Nicholas Glozier
-
-
Queensland
-
Maroochydore, Queensland, 호주, 4558
- 모병
- Thompson Brain & Mind Healthcare (TBMH)
-
수석 연구원:
- Adem Can
-
연락하다:
- Megan Dutton
- 전화번호: +61 4160 40977
- 이메일: mdutton@tbmh.org.au
-
연락하다:
- Kristy Smyth
- 전화번호: +61 4324 41227
- 이메일: ksmyth@tbmh.org.au
-
-
Victoria
-
Melbourne, Victoria, 호주, 3004
- 모병
- Ramsay Clinic
-
수석 연구원:
- Malcolm Hopwood
-
연락하다:
- Melanie Hurley
- 전화번호: 03 9279 3569
- 이메일: research.arc@ramsayhealth.com.au
-
연락하다:
- Grace Monigatti
- 전화번호: 03 9279 3569
- 이메일: research.arc@ramsayhealth.com.au
-
Melbourne, Victoria, 호주, 3053
- 모병
- Neurocentrix Research
-
수석 연구원:
- David Barton
-
연락하다:
- Mai-Anh Bui
- 전화번호: +61 3 9546 0009
- 이메일: mai@neurocentrix.com.au
-
연락하다:
- Gabriela Gonzalez
- 전화번호: +61 3 9959 8375
- 이메일: gabriela@neurocentrix.com.au
-
Notting Hill, Victoria, 호주, 3168
- 모병
- Monash University - Notting Hill
-
연락하다:
- Olivia Lavalette
- 전화번호: 0426359494
- 이메일: olivia.lavalette@monash.edu
-
수석 연구원:
- Paul Liknaitzky
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
Participants must meet all the following criteria to be included in the trial:
- Age18 to 85 years.
- Participant has a diagnosis of MDD (single or recurrent episode as defined by DSM-5 TR [if single episode, duration of ≥4 weeks and ≤24 months] and established as per evaluation by the Investigator. The first MDD episode must have occurred prior to age 60.
- Moderate to severe depression at Screening and Baseline, independently confirmed.
- Participants have been on a stable dose of antidepressant medication (label specified) at an adequate dose in the last 4 weeks prior to Screening and has had an inadequate response (less than 50% improvement), as judged by the Investigator.
- Participant has a body mass index (BMI) of 40 kg/m2 or less (BMI ≤40 kg/m2), inclusive, at Screening.
- Participant is able to refrain from nicotine use during the dosing session (up to 8 hours).
- Participants capable of producing sperm must use a condom plus spermicide during the trial and for 12 weeks after their final dose of trial medication, if their partner is a person of childbearing potential.
- Participants of childbearing potential who have a partner capable of producing sperm must agree to use a highly effective method of contraception in combination with the use of a condom plus spermicide during the trial and for 12 weeks after their final dose of trial medication. Such participants must have a negative pregnancy test at Screening and Day 1 prior to dosing.
- Participants of non-childbearing potential who are or were capable of producing eggs (ova) must have been postmenopausal or permanently sterile following hysterectomy, bilateral salpingectomy, or bilateral oophorectomy.
- Participants have provided written informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form.
Exclusion Criteria
Participants with any of the following characteristics/conditions will be excluded from trial participation:
- Current or previously diagnosed schizophrenia spectrum or other psychotic disorders, including schizophrenia, schizoaffective disorder, schizotypal disorder, schizophreniform disorder, brief psychotic disorder, current or previous history of bipolar disorder, or current borderline personality disorder.
- Participants with a medical diagnosis of attention deficit hyperactivity disorder (ADHD) will be excluded if currently taking medication for ADHD.
- Family history of schizophrenia, schizoaffective disorder, or bipolar disorder type 1 (first-degree relatives).
- Significant suicide risk within the past 6 months, during the Screening Period, or at Baseline; or (b) suicidal behaviors within 12 months of Screening; or (c) clinical assessment of significant suicidal risk during clinical interview; or (d) non-suicidal self-injury within 12 months of Screening.
- Current or previous diagnosis of treatment-resistant MDD, defined as failure to respond to 2 or more antidepressant treatments of 2 different classes given at an adequate dose (label specified) for an adequate duration as judged by the Investigator and clinical interview.
- Has had electroconvulsive treatment, transcranial magnetic stimulation, deep brain stimulation, or vagal nerve stimulation for any episode of MDD in the last 6 months.
- Currently receiving a monoamine oxidase inhibitor, tricyclic antidepressants, mirtazapine, trazodone, moclobemide, buspirone, or an antipsychotic or mood stabilizer. Note: if receiving these medications are for another indication, they must be discontinued ≥ 14 days or 5 half-lives, whichever is longer, prior to Day 1.
- Participant report of (or if available in medical record) exposure to psilocin, or 5-HT2a receptor agonists, or any other psychedelics, such as ayahuasca, mescaline, lysergic acid diethylamide, peyote, or 3,4-methylenedioxymethamphetamine, more than 10 times over the participant's lifetime or any psychedelic use within 12 months prior to Screening.
- Participant report of (or if available in medical record) treatment with ketamine or S-ketamine use within 6 months prior to Screening.
- Clinically relevant history of abnormal physical health interfering with the trial (including but not limited to, neurological, cardiovascular, respiratory, gastrointestinal [including dyspepsia or gastroesophageal reflux disease], hepatic, or renal disorder).
- Has hypothyroidism or hyperthyroidism, unless controlled on appropriate medication.
- Current diagnosis of uncontrolled hypertension or an arrhythmia, or clinically relevant abnormal results for heart rate.
- Participants have a presence or relevant history of organic brain disorders.
- Participant is taking or has taken OTC doses of 5-HTP or St John's Wort within prior to trial medication administration.
- Donation of blood or plasma within 4 weeks prior to first dosing and until 4 weeks after final dosing.
- Participants capable of producing sperm who will not abstain from sperm donation between first dosing and 12 weeks after final dosing.
- Participants of childbearing potential who are pregnant, breastfeeding, planning to conceive or unwilling to abstain from egg (ova) donation between first dosing and 12 weeks after final dosing.
- History of serotonin syndrome.
- Unwilling to consent to audio and video recording of psychological support and dosing sessions.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Experimental Arm A CYB003 in 2 of 2 Dosing Sessions
Arm A participants will receive 8 mg of CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. All Arm A participants will continue on their current antidepressants and receive psychological support throughout the study. |
CYB003 is a deuterated psilocin analog. Manualized psychological support performed by facilitator. |
|
실험적: Experimental Arm B CYB003 in 2 of 2 Dosing Sessions
Experimental Arm B participants will receive 16 mg of CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. All Arm B participants will continue on their current antidepressants and receive psychological support throughout the study. |
CYB003 is a deuterated psilocin analog. Manualized psychological support performed by facilitator. |
|
위약 비교기: Placebo Comparator: Arm C Placebo in 2 of 2 Dosing Session
Participants will receive placebo in 2 of 2 medicine sessions, approximately three weeks apart. All Arm C participants will continue on their current antidepressants and receive psychological support throughout the study. Non-responders will be eligible to receive CYB003 in a subsequent extension trial. |
Manualized psychological support performed by facilitator. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Montgomery-Asberg Depression Scale (MADRS)
기간: Screening Day-45, Baseline, Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.
|
The MADRS is a 10-item scale with ratings based on a clinical interview which moves from broadly phased questions about symptoms to more detailed ones allowing a precise rating of severity. The total score ranges 0-60, higher scores denote greater severity. |
Screening Day-45, Baseline, Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
The Beck Depression Inventory - Second Edition (BDI-II)
기간: Day -1, Day 21, Day 42 and Day 84/End of Trial.
|
The Beck Depression Inventory-Second Edition (BDI-II) is a 21-question multiple-choice self-report inventory, assessing depressive symptoms and severity. Each question is scored on a scale value of 0 to 3, with higher total scores indicating more severe depressive symptoms. Each of the 21 items corresponding to a symptom of depression is summed to give a single score for the BDI-II, so the total score possible is 63 and minimum if everything is zero would be 0. |
Day -1, Day 21, Day 42 and Day 84/End of Trial.
|
|
The Clinical Global Impression Scale (CGI-S)
기간: Screening Day-45, Baseline Day -1, Day 42, Day 84/End of Trial.
|
The Clinical Global Impression Scale is a clinician-rated instrument comprised of 3 global measures: severity of illness, global improvement and efficacy index. Only the severity of illness ang global improvement measures will be utilized for this trial. Higher score means more severe symptomology, worse outcome. CGI-S scoring is as follows:
|
Screening Day-45, Baseline Day -1, Day 42, Day 84/End of Trial.
|
|
The Generalized Anxiety Disorder 7-Item Scale (GAD-7)
기간: Baseline Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.
|
The Generalized Anxiety Disorder 7-Item Scale (GAD-7) is a 7-item self reported assessment that measures the severity of generalized anxiety disorder symptoms. Participants respond to each item using a 4-point scale from 0 to 3. Participants choose one of 4 severity scores associated with problems related to the common anxiety disorders to indicate the degree to which these problems caused functional and/or social difficulties. A total score is obtained by the sum of all total column values, higher scores indicate more functional/social impairment/difficulties. Score range is as follows: Scores represent: 0 - 4 = Minimal anxiety 5 - 9 = Mild anxiety 10 - 14 = Moderately anxiety 15 - 21 = Severe anxiety |
Baseline Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.
|
|
The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF)
기간: Day -1, Day 21, Day 42 and Day 84/End of Trial.
|
The original Quality of Life Enjoyment and Satisfaction Questionnaire is a 93 item, participant facing, self reported measure used to evaluate intervention-related changes in quality of life, divided int the following sections: physical health, feelings, work, household duties, school, leisure time activities, social relations and general activities. The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) version will be used in this trial. Each item rated on a 5-point scale ranging from 1 (very poor) to 5 (very good), higher score indicates greater satisfaction. The scoring of the Q-LES-Q-SF involves summing only the first 14 items to yield a raw total score. The last two items are not included in the total score but are standalone items. The raw total score ranges from 14 to 70. So the minimum raw score on the Q-LES-Q-SF is 14, and the maximum score is 70 |
Day -1, Day 21, Day 42 and Day 84/End of Trial.
|
공동 작업자 및 조사자
간행물 및 유용한 링크
유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .